Kezdőlap・Részvénylista・DexCom Inc

DexCom Inc

Lezárt

SzektorEgészségügy

86.95 -0.29

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

85.87

Maximum

87.73

Fő mutatók
By Trading Economics
Bevétel	50M 249M
Értékesítés	117M 1.3B
P/E Szektor átlag	34.51 68.51
Egy részvényre jutó nyereség	0.7
Profit margin	19.039
Munkavállalók	11,000
EBITDA	52M 389M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+3.68% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. okt. 29.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	4.6B 33B
Előző nyitás	87.24
Előző zárás	86.95

Hangulat hírek alapján

By Acuity

21%

79%

64 / 340 Rangsor szerint Healthcare

DexCom Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

2026. aug. 3. 20:02 UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

2026. júl. 31. 20:04 UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

2026. júl. 30. 23:51 UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

2026. júl. 29. 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

2026. júl. 28. 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

2026. júl. 27. 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

2026. júl. 24. 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

2026. júl. 22. 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

2026. júl. 21. 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

2026. júl. 20. 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Társak összehasonlítása

Árváltozás

DexCom Inc Előrejelzés

Célár

By TipRanks

3.68% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 90.52 USD 3.68%

Magas 112 USD

Alacsony 64 USD

23 Wall Street elemző 12 hónapos célárain alapulva a(z)DexCom Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

23 ratings

Vétel

Tartás

Eladás

23 Wall Street elemző célárain alapulva a(z)DexCom Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

64 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.